Although breast cancer at advanced or metastatic stage is currently incurable, relevant research has confirmed that Ribociclib, a CDK4/6 inhibitor, can significantly prolong the overall survival of premenopausal HR+/HER2-advanced breast cancer patients. Also, it can combine with fulvestrant as second-line therapy.
Breast cancer is a big threat for women. Each year, large number of people are diagnosed with advanced breast cancer. However, a heart-breaking fact can not be neglected that the annual survival rate is as low as only 20%, and the overall median survival time is 2 to 3 years. This is partly because of late detection, and partly because of limited treatment options. Over the past ten years, only chemotherapy or endocrine therapy are available. But luckily, the discovery of the potential of CDK4/6 inhibitors in the treatment of advanced breast cancer has added more options, which greatly advances treatment in this field.
So what is CDK4/6? CDK4/6 are cyclin-dependent kinases 4 and 6, which are key regulators of the cell division cycle and can drive cell division. At the same time, CDK4/6 is over-actively expressed in many cancers, leading to uncontrolled cell division cycles, which is a hallmark feature of cancer. CDK4/6 inhibitors can block tumor cell proliferation and have a synergistic effect with endocrine therapy.
Previously, the indications for the approval of CDK4/6 inhibitors were mainly used in postmenopausal hormone receptor-positive and HER2-negative advanced breast cancer patients. In July 2018, Ribociclib became the first drug to pass the FDA’s Real-Time Oncology Review and was approved for use with aromatase inhibitors for hormone receptor (HR) -positive, human epidermal growth factor Receptor 2 (HER2) -negative advanced or metastatic breast cancer.
Ribociclib combined with Fulvestrant (FUL) reduced the risk of death by 30%. The treatment group reduced the risk of death by 27%. In addition, the efficacy of Ribociclib combined with letrozole or anastrozole was better than that of single drugs, and progression-free survival (PFS) could be nearly doubled.
The advancement of medicine will always give people hope. These clinical studies show that the unique mechanism of action of the innovative drug regimen of CDK4/6 inhibitors can penetrate the entire course of breast cancer treatment and is expected to be used for all hormones before and after menopause.
Prevention measures
Some women have an increased chance of developing breast cancer, while others have a below-average incidence. The factors that increase breast cancer risk are wide-ranged, including: aging, excessive high doses of radiation to the chest, long-term use of exogenous estrogen, postmenopausal obesity, and long-term excessive drinking. Moreover, scientist also found that some mutations genes are associated with breast cancer, such as BRCA-1, BRCA-2, p53, and PTEN. This doesn’t mean that women with several high-risk factors will necessarily develop into breast cancer. Actually, regular exercise, especially during adolescence or early adulthood, may reduce the risk of breast cancer.
The following aspects can be considered in the prevention of breast cancer:
1. Establish a good lifestyle, adjust the pace of life, and maintain a comfortable mood.
2. Keep physical exercise, actively participate in social activities, avoid and reduce mental and psychological pressures, and maintain a peaceful mindset.
3. Develop good eating habits. Pay attention to nutritional balance in infants and children and promote breastfeeding; reduce excessive intake of high-protein and low-fiber diets during child development; do not consume large amounts of fat and animal protein during adolescence, and strengthen physical exercise; control total calorie intake after menopause obesity
4. Do not mess with exogenous estrogen.
5. No long-term excessive drinking.
6. Carry out drug-based prevention in high-risk groups of breast cancer. The National Cancer Center has conducted exploratory research on the prevention of breast cancer with drugs such as tamoxifen and raloxifene.

Author's Bio: 

BOC Sciences